Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca reports positive results from Phase III trial of exenatide in type 2 diabetes British drug-maker AstraZeneca has reported positive results from a 28-week Phase III trial of exenatide to treat adult patients with type 2 diabetes. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Cytori gets FDA nod to resume enrolment in ATHENA cardiovascular trial
By PBR Staff Writer
Cytori Therapeutics has received notification from the US Food and Drug Administration (FDA) that the company has provided additional information sufficient to support continuation of enrollment in its ATHENA cardiovascular trials.
News
Islet and BHV report two Phase IIb clinical trials of remogliflozin etabonate to treat type 2 diabetes
Islet Sciences has announced the publication of two peer-reviewed articles highlighting clinical results from completed 12-week Phase 2b studies of remogliflozin etabonate, a selective sodium glucose transporter 2 (SGLT2) inhibitor currently being developed by Brighthaven Ventures for type 2 diabetes and nonalcoholic steatohepatitis (NASH).
News

Contract Research

Roche to invest $3.2bn in Basel site development
By PBR Staff Writer
Swiss health-care firm Roche is planning to invest CHF3bn ($3.2bn) over the next ten years on development work at its Basel site, including CHF1.7bn ($1.8bn) on the construction of a new research and development (R&D) centre.
News
Leading Researchers join Biogen Idec to advance drug discovery for neurodegenerative diseases
Biogen Idec announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases.
News

Contract Services

Medivation licenses anti-PD-1 immune modulatory monoclonal antibody from CureTech
Medivation, and CureTech, announced Medivation has licensed exclusive worldwide rights to CureTech's late-stage clinical molecule pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody.
News
Iroko inks new licensing deal with Landsteiner Scientific to market Zorvolex in Mexico
By PBR Staff Writer
Iroko Pharmaceuticals has signed a licensing agreement with Landsteiner Scientific for the exclusive rights to market and sell Zorvolex (diclofenac) capsules in Mexico.
News